| Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays MG Manfredi, JA Ecsedy, A Chakravarty, L Silverman, M Zhang, KM Hoar, ... Clinical cancer research 17 (24), 7614-7624, 2011 | 325 | 2011 |
| MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy K Hoar, A Chakravarty, C Rabino, D Wysong, D Bowman, N Roy, ... Molecular and cellular biology, 2007 | 259 | 2007 |
| Growth rate analysis and efficient experimental design for tumor xenograft studies: supplementary issue: array platform modeling and analysis (A) G Hather, R Liu, S Bandi, J Mettetal, M Manfredi, WC Shyu, J Donelan, ... Cancer informatics 13, CIN. S13974, 2014 | 140 | 2014 |
| SCOPE: a web server for practical de novo motif discovery JM Carlson, A Chakravarty, CE DeZiel, RH Gross Nucleic acids research 35 (suppl_2), W259-W264, 2007 | 129 | 2007 |
| Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics T Macarulla, A Cervantes, E Elez, E Rodríguez-Braun, J Baselga, ... Molecular cancer therapeutics 9 (10), 2844-2852, 2010 | 96 | 2010 |
| Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, M Rogers, ... PloS one 16 (4), e0250780, 2021 | 72 | 2021 |
| The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents DR Wysong, A Chakravarty, K Hoar, JA Ecsedy Cell cycle 8 (6), 876-888, 2009 | 71 | 2009 |
| A novel ensemble learning method for de novo computational identification of DNA binding sites A Chakravarty, JM Carlson, RS Khetani, RH Gross BMC bioinformatics 8, 1-15, 2007 | 70 | 2007 |
| A mechanistic model for the organization of microtubule asters by motor and non-motor proteins in a mammalian mitotic extract A Chakravarty, L Howard, DA Compton Molecular biology of the cell 15 (5), 2116-2132, 2004 | 60 | 2004 |
| Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase A Chakravarty, V Shinde, J Tabernero, A Cervantes, RB Cohen, EC Dees, ... Cancer research 71 (3), 675-685, 2011 | 54 | 2011 |
| Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape E Schuck, T Bohnert, A Chakravarty, V Damian-Iordache, C Gibson, ... The AAPS journal 17, 462-473, 2015 | 52 | 2015 |
| Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines DL Driscoll, A Chakravarty, D Bowman, V Shinde, K Lasky, J Shi, T Vos, ... PloS one 9 (11), e111060, 2014 | 52 | 2014 |
| Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib) JJ Huck, M Zhang, J Mettetal, A Chakravarty, K Venkatakrishnan, X Zhou, ... Molecular cancer therapeutics 13 (9), 2170-2183, 2014 | 42 | 2014 |
| SPACER: identification of cis-regulatory elements with non-contiguous critical residues A Chakravarty, JM Carlson, RS Khetani, CE DeZiel, RH Gross Bioinformatics 23 (8), 1029-1031, 2007 | 38 | 2007 |
| Bounded search for de novo identification of degenerate cis-regulatory elements JM Carlson, A Chakravarty, RS Khetani, RH Gross BMC bioinformatics 7, 1-17, 2006 | 34 | 2006 |
| BEAM: a beam search algorithm for the identification of cis-regulatory elements in groups of genes JM Carlson, A Chakravarty, RH Gross Journal of Computational Biology 13 (3), 686-701, 2006 | 34 | 2006 |
| Individually optimal choices can be collectively disastrous in COVID-19 disease control M Stoddard, D Van Egeren, KE Johnson, S Rao, J Furgeson, DE White, ... BMC public health 21, 1-12, 2021 | 28 | 2021 |
| Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase S Palani, M Patel, J Huck, M Zhang, SK Balani, J Yang, S Chen, J Mettetal, ... Cancer chemotherapy and pharmacology 72, 1255-1264, 2013 | 28 | 2013 |
| Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, M Rogers, ... medRxiv, 2020.11. 17.20233726, 2020 | 26 | 2020 |
| Dose optimization for anticancer drug combinations: maximizing therapeutic index via clinical exposure-toxicity/preclinical exposure-efficacy modeling DC Bottino, M Patel, E Kadakia, J Zhou, C Patel, R Neuwirth, N Iartchouk, ... Clinical Cancer Research 25 (22), 6633-6643, 2019 | 26 | 2019 |
